Company profile for Ever Pharma

PharmaCompass

Ever Pharma, highly specialized CDMO in producing complex injectables including high potency & controlled substances & suspensions.

Related CompaniesRelated Companies

About

EVER Pharma is a fully integrated specialty pharmaceuticals company focused on the research, development, production, and commercialization of products in the areas of neurology and specialty injectables, covering oncology, intensive care and hormone therapeutics. From our headquarters in Austria, we run a dynamic operation providing innovative products and value-added formulations aimed at enhancing the lives of patients and supporting the work of healthcare professionals through improved convenience and safety.

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
Austria
Address
Address
Oberburgau 3, 4866 Unterach
Telephone
Telephone
+43 7665205550
Twitter
Twitter
Contact Info
Others

Events

Webinars & Exhibitions

Default Event

DCAT Week

Not Confirmed

envelop Contact Supplier

DCAT Week

Post an Enquiry

Meeting

Digital content read-more

Explore the latest content creation from this company

CORPORATE CONTENT #SupplierSpotlight

    https://www.pharmacompass.com/pdf/party/content/ever-pharma-party-content-39961.pdf

    https://www.pharmacompass.com/pdf/party/content/ever-pharma-party-content-46564.pdf

NEWS #PharmaBuzz

read-more
read-more

https://www.everpharma.com/news/ever-pharma-gained-eu-approval-of-testosterone-enantate/

PRESS RELEASE
19 Aug 2024

https://www.globenewswire.com/news-release/2024/08/14/2930389/0/en/Silo-Pharma-Expands-Development-Agreement-with-Sever-Pharma-for-Novel-Ketamine-Implant-Therapeutic.html

GLOBENEWSWIRE
14 Aug 2024

https://www.everpharma.com/news/ever-pharma-gained-eu-approval-for-advanced-cancer-treatment/

PRESS RELEASE
16 Apr 2024

https://www.everpharma.com/news/ever-pharma-announces-approval-of-testosterone-undecanoate-in-the-eu/

PRESS RELEASE
13 Mar 2024

https://www.everpharma.com/news/ever-pharma-gains-eu-marketing-authorization-for-trabectedin/

PRESS RELEASE
22 Jun 2023

https://www.everpharma.com/news/ever-pharma-expands-operations-with-opening-of-new-manufacturing-facility-in-jena-germany/

PRESS RELEASE
10 Mar 2023

Drugs in Development

read-more
read-more

Details:

Testosterone enantate EVER Pharma is an androgen receptor agonist indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency of endogenous testosterone.


Lead Product(s): Testosterone Enanthate

Therapeutic Area: Endocrinology Brand Name: Testosterone Enantate Ever Pharma

Study Phase: ApprovedProduct Type: Small molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable August 19, 2024

Ever Pharma CB

01

Ever Pharma

Austria
arrow
Antibody Engineering
Not Confirmed

Lead Product(s) : Testosterone Enanthate

Therapeutic Area : Endocrinology

Highest Development Status : Approved

Partner/Sponsor/Collaborator : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

Details : Testosterone enantate EVER Pharma is an androgen receptor agonist indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency of endogenous testosterone.

Brand Name : Testosterone Enantate Ever Pharma

Molecule Type : Small molecule

Upfront Cash : Not Applicable

August 19, 2024

Ever Pharma CB

Details:

Eribulin EVER Pharma is a microtubule inhibitor which is indicated for the treatment of locally advanced or metastatic breast cancer and unresectable liposarcoma.


Lead Product(s): Eribulin

Therapeutic Area: Oncology Brand Name: Eribulin EVER Pharma

Study Phase: ApprovedProduct Type: Small molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable August 16, 2024

Ever Pharma CB

02

Ever Pharma

Austria
arrow
Antibody Engineering
Not Confirmed

Lead Product(s) : Eribulin

Therapeutic Area : Oncology

Highest Development Status : Approved

Partner/Sponsor/Collaborator : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

Details : Eribulin EVER Pharma is a microtubule inhibitor which is indicated for the treatment of locally advanced or metastatic breast cancer and unresectable liposarcoma.

Brand Name : Eribulin EVER Pharma

Molecule Type : Small molecule

Upfront Cash : Not Applicable

August 16, 2024

Ever Pharma CB

Details:

Testosterone undecanoate EVER Pharma is an androgen receptor agonist indicated for testosterone replacement therapy in males for conditions associated with a deficiency of endogenous testosterone.


Lead Product(s): Testosterone Undecanoate

Therapeutic Area: Endocrinology Brand Name: Testosterone Undecanoate EVER Pharma

Study Phase: ApprovedProduct Type: Small molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable August 13, 2024

Ever Pharma CB

03

Ever Pharma

Austria
arrow
Antibody Engineering
Not Confirmed

Lead Product(s) : Testosterone Undecanoate

Therapeutic Area : Endocrinology

Highest Development Status : Approved

Partner/Sponsor/Collaborator : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

Details : Testosterone undecanoate EVER Pharma is an androgen receptor agonist indicated for testosterone replacement therapy in males for conditions associated with a deficiency of endogenous testosterone.

Brand Name : Testosterone Undecanoate EVER Pharma

Molecule Type : Small molecule

Upfront Cash : Not Applicable

August 13, 2024

Ever Pharma CB

Details:

EVER Pharma has received the EU-wide marketing authorization of Trabectedin EVER Pharma, which is available in 0.25mg and 1mg vial sizes for treating advanced soft tissue sarcoma and ovarian cancer.


Lead Product(s): Trabectedin

Therapeutic Area: Oncology Brand Name: Trabectedin EVER Pharma

Study Phase: ApprovedProduct Type: Small molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 22, 2024

Ever Pharma CB

04

Ever Pharma

Austria
arrow
Antibody Engineering
Not Confirmed

Lead Product(s) : Trabectedin

Therapeutic Area : Oncology

Highest Development Status : Approved

Partner/Sponsor/Collaborator : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

Details : EVER Pharma has received the EU-wide marketing authorization of Trabectedin EVER Pharma, which is available in 0.25mg and 1mg vial sizes for treating advanced soft tissue sarcoma and ovarian cancer.

Brand Name : Trabectedin EVER Pharma

Molecule Type : Small molecule

Upfront Cash : Not Applicable

June 22, 2024

Ever Pharma CB

Details:

Bortezomib EVER Pharma is a proteasome inhibitor small molecule drug candidate, which is indicated for the treatment of patients with multiple myeloma and mantle cell lymphoma.


Lead Product(s): Bortezomib

Therapeutic Area: Oncology Brand Name: Bortezomib EVER Pharma

Study Phase: ApprovedProduct Type: Small molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 09, 2022

Ever Pharma CB

05

Ever Pharma

Austria
arrow
Antibody Engineering
Not Confirmed

Lead Product(s) : Bortezomib

Therapeutic Area : Oncology

Highest Development Status : Approved

Partner/Sponsor/Collaborator : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

Details : Bortezomib EVER Pharma is a proteasome inhibitor small molecule drug candidate, which is indicated for the treatment of patients with multiple myeloma and mantle cell lymphoma.

Brand Name : Bortezomib EVER Pharma

Molecule Type : Small molecule

Upfront Cash : Not Applicable

February 09, 2022

Ever Pharma CB

Details:

Azacitidine EVER Pharma is a DNMT1/DNMT3A indicated for the treatment of myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia.


Lead Product(s): Azacitidine

Therapeutic Area: Oncology Brand Name: Azacitidine EVER Pharma

Study Phase: ApprovedProduct Type: Small molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 12, 2021

Ever Pharma CB

06

Ever Pharma

Austria
arrow
Antibody Engineering
Not Confirmed

Lead Product(s) : Azacitidine

Therapeutic Area : Oncology

Highest Development Status : Approved

Partner/Sponsor/Collaborator : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

Details : Azacitidine EVER Pharma is a DNMT1/DNMT3A indicated for the treatment of myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia.

Brand Name : Azacitidine EVER Pharma

Molecule Type : Small molecule

Upfront Cash : Not Applicable

March 12, 2021

Ever Pharma CB

Details:

EVER Pharma has received EU-wide marketing authorization of Pemetrexed EVER Pharma for the treatment of patients with malignant pleural mesothelioma and non-small cell lung cancer.


Lead Product(s): Pemetrexed

Therapeutic Area: Oncology Brand Name: Pemetrexed EVER Pharma

Study Phase: ApprovedProduct Type: Small molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable December 15, 2020

Ever Pharma CB

07

Ever Pharma

Austria
arrow
Antibody Engineering
Not Confirmed

Lead Product(s) : Pemetrexed

Therapeutic Area : Oncology

Highest Development Status : Approved

Partner/Sponsor/Collaborator : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

Details : EVER Pharma has received EU-wide marketing authorization of Pemetrexed EVER Pharma for the treatment of patients with malignant pleural mesothelioma and non-small cell lung cancer.

Brand Name : Pemetrexed EVER Pharma

Molecule Type : Small molecule

Upfront Cash : Not Applicable

December 15, 2020

Ever Pharma CB

Details:

Cabazitaxel EVER Pharma in combination with prednisone or prednisolone is indicated for the treatment of patients with metastatic castration resistant prostate cancer.


Lead Product(s): Cabazitaxel,Prednisone

Therapeutic Area: Oncology Brand Name: Cabazitaxel EVER Pharma

Study Phase: ApprovedProduct Type: Small molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable October 21, 2020

Ever Pharma CB

08

Ever Pharma

Austria
arrow
Antibody Engineering
Not Confirmed

Lead Product(s) : Cabazitaxel,Prednisone

Therapeutic Area : Oncology

Highest Development Status : Approved

Partner/Sponsor/Collaborator : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

Details : Cabazitaxel EVER Pharma in combination with prednisone or prednisolone is indicated for the treatment of patients with metastatic castration resistant prostate cancer.

Brand Name : Cabazitaxel EVER Pharma

Molecule Type : Small molecule

Upfront Cash : Not Applicable

October 21, 2020

Ever Pharma CB
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Europe

read-more
read-more

01

Brand Name : Dacepton

Ever Pharma

Dosage Form : INJECTION / INFUSION

Dosage Strength : 10 MG / ML

Packaging :

Brand Name : Dacepton

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Sweden

Ever Pharma CB

02

Brand Name : Dacepton

Ever Pharma

Dosage Form : SOLUTION FOR INFUSION

Dosage Strength : 5 MG / ML

Packaging :

Brand Name : Dacepton

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Sweden

Ever Pharma CB

03

Brand Name : Trabectedin EVER Pha...

Ever Pharma

Dosage Form : Powder for concentrate for inf...

Dosage Strength : 0.25 mg

Packaging : Vials 1 0.25mg

Brand Name : Trabectedin EVER Pharma

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Norway

Ever Pharma CB

04

Brand Name : Trabectedin EVER Pha...

Ever Pharma

Dosage Form : Powder for concentrate for inf...

Dosage Strength : 1 mg

Packaging : Vials 1 1mg

Brand Name : Trabectedin EVER Pharma

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Norway

Ever Pharma CB
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Services

Discover the service capabilities from this company

Drug Product Manufacturing

Discover their expertise for : Drug Product Manufacturing

Liquid

read-more
read-more

02

arrow
Antibody Engineering
Not Confirmed
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothEver Pharma, highly specialized CDMO in producing complex injectables including high potency & controlled substances & suspensions.

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothEver Pharma, highly specialized CDMO in producing complex injectables including high potency & controlled substances & suspensions.

Pharma Service : Drug Product Manufacturing

03

arrow
Antibody Engineering
Not Confirmed
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothEver Pharma, highly specialized CDMO in producing complex injectables including high potency & controlled substances & suspensions.

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothEver Pharma, highly specialized CDMO in producing complex injectables including high potency & controlled substances & suspensions.

Pharma Service : Drug Product Manufacturing

Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Injectable / Parenteral

read-more
read-more
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

API & Drug Product Development

Discover their expertise for : API & Drug Product Development

KEY SERVICES

read-more
read-more

TOP RANKED SUPPLIER FOR:

Sterile Injectable Manufacturing
full-view
Injectable Suspensions
full-view

Inspections and registrations

Check the inspections & registration from this company

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty